SKYSEQ

Serial Number 90590474
Registration 7754868
700

Registration Progress

Application Filed
Mar 19, 2021
Under Examination
Aug 30, 2022
Approved for Publication
Jul 5, 2022
Published for Opposition
Jul 5, 2022
Registered
Apr 8, 2025

Trademark Image

SKYSEQ

Basic Information

Serial Number
90590474
Registration Number
7754868
Filing Date
March 19, 2021
Registration Date
April 8, 2025
Published for Opposition
July 5, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 8, 2025
Registration
Registered
Classes
042

Rights Holder

Skyhawk Therapeutics, Inc.

03
Address
180 3rd Avenue, Fifth Floor
Waltham, MA 02451

Ownership History

Skyhawk Therapeutics, Inc.

Original Applicant
03
Waltham, MA

Skyhawk Therapeutics, Inc.

Owner at Publication
03
Waltham, MA

Skyhawk Therapeutics, Inc.

Original Registrant
03
Waltham, MA

Legal Representation

Attorney
Peter Kunin

USPTO Deadlines

Next Deadline
1893 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250408)
Due Date
April 08, 2031
Grace Period Ends
October 08, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

42 events
Date Code Type Description Documents
Apr 8, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Apr 8, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Mar 20, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Mar 20, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Nov 1, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 1, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 1, 2024 ALIE A ASSIGNED TO LIE Loading...
Oct 24, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Oct 18, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 18, 2024 GNRT O NON-FINAL ACTION E-MAILED Loading...
Oct 18, 2024 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Aug 27, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 6, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 28, 2024 IUAF S USE AMENDMENT FILED Loading...
Jul 6, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 28, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Feb 20, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 19, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 19, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Feb 19, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 23, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 21, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Aug 21, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Aug 21, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 24, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 22, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 22, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 22, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 30, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 5, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 5, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 15, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 1, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 26, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 26, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 26, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Oct 27, 2021 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Oct 27, 2021 GPRA F PRIORITY ACTION E-MAILED Loading...
Oct 27, 2021 CPRA R PRIORITY ACTION WRITTEN Loading...
Oct 21, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 22, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 23, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Research and development of pharmaceuticals, namely, small molecule therapies for the alteration of RNA splicing and expression, used in the treatment of cancers, neurological diseases, infectious diseases and other diseases using integrated and high-throughput screening technologies coupled with next-generation sequencing
First Use Anywhere: Apr 8, 2024
First Use in Commerce: Apr 8, 2024

Classification

International Classes
042